Pulmatrix Inc. (PULM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Pulmatrix Inc. (PULM) dropped -5.67% to $1.42, trading at 7% of its 52-week range ($1.16 – $4.99). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling Development
In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)“Speedy,” a PTC-2105-treat
Eos SENOLYTIX, Inc. ("Eos" or the "Company") a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and
https://patentcenter.uspto.gov/applications/18548896/ifw/docs
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PULM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PULM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Pulmatrix Inc. (PULM) ranks #802 by composite RQD confidence (36/100, grade D-) and #944 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, PULM leads on earnings valuation at N/A trailing P/E, while XBIO leads on capital efficiency and profitability with -30.3% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 57/100 (D+) compared with PULM at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PULM
ACTIVE
Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -5.67% | $5.2M | Benchmark Subject |
| PCSA Processa Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +2.16% | $5.3M | /pcsa-vs-pulm → |
| CANF Can-Fite Biopharma Ltd each representing two (2) | E | 31/100 | — | — | -35.0% | +0.61% | $5.0M | /canf-vs-pulm → |
| ADXN Addex Therapeutics Ltd | D+ | 57/100 | — | — | — | -1.01% | $5.0M | /adxn-vs-pulm → |
| XBIO Xenetic Biosciences Inc. | D | 47/100 | — | — | -30.3% | +0.95% | $5.0M | /xbio-vs-pulm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulmatrix Inc. (PULM) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $7.8M , and -100.0% cumulative change since FY2023) , GAAP net income of -$5.2M, operating cash flow of -$5.4M, and free cash flow of -$5.4M (+51.1% YoY). On the balance sheet, PULM closed FY2025 with $4.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$5.2M | -$5.4M | -$5.4M | $4.1M | — |
| FY2024 (FY) | 2024-12-31 | $7.8M | -$9.6M | -$10.7M | -$11.1M | $9.9M | — |
| FY2023 (FY) | 2023-12-31 | $7.3M | -$14.1M | -$16.0M | -$16.0M | — | — |
As of 2026-11-01, Pulmatrix Inc. (NASDAQ: PULM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.42 (-5.67% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PULM ranks #802 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PULM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PCSA (Processa Pharmaceuticals Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and CANF (Can-Fite Biopharma Ltd each representing two (2)) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $5.0M). Among the 5-stock peer group, PULM leads on earnings multiple (N/A) while XBIO leads on capital efficiency (-30.3% ROIC).
Per PULM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574235), Pulmatrix Inc. generated $0 in revenue (-100.0% YoY), -$5.2M in net income, and -$5.4M in free cash flow against $4.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PULM last traded at $1.42 (-5.67% on volume of 5,908 shares), positioning the stock -4.70% below its 50-day simple moving average ($1.49) and -16.96% below its 200-day simple moving average ($1.71). Across its 52-week range of $1.16 to $4.99, PULM sits at the 6.8% percentile with a 14-day RSI of 44.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.24 to $1.60).
Why PULM Stock dropped -5.67% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.